China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.4
24.61
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
Price Targets Summary
China Resources Double-Crane Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 27.46 CNY with a low forecast of 25.25 CNY and a high forecast of 31.25 CNY.
Price Targets
Revenue
Forecast
Revenue Estimate
China Resources Double-Crane Pharmaceutical Co Ltd
For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's revenue is 9%. The projected CAGR for the next 3 years is 8%.
Operating Income
Forecast
Operating Income Estimate
China Resources Double-Crane Pharmaceutical Co Ltd
For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's operating income is 10%. The projected CAGR for the next 3 years is 15%.
Net Income
Forecast
Net Income Estimate
China Resources Double-Crane Pharmaceutical Co Ltd
For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's net income is 9%. The projected CAGR for the next 3 years is 16%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is China Resources Double-Crane Pharmaceutical Co Ltd's stock price target?
Price Target
27.46
CNY
According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 27.46 CNY with a low forecast of 25.25 CNY and a high forecast of 31.25 CNY.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
8%
For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's revenue is 9%. The projected CAGR for the next 3 years is 8%.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
15%
For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's operating income is 10%. The projected CAGR for the next 3 years is 15%.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
16%
For the last 8 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's net income is 9%. The projected CAGR for the next 3 years is 16%.
You don't have any saved screeners yet
